Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $35,070.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 835 shares of the stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $42.00, for a total value of $35,070.00. Following the sale, the director now directly owns 334,646 shares in the company, valued at $14,055,132. This represents a 0.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Pro-Dex Stock Performance

Shares of NASDAQ:PDEX opened at $40.66 on Friday. Pro-Dex, Inc. has a 1 year low of $16.18 and a 1 year high of $59.60. The stock has a market capitalization of $132.55 million, a price-to-earnings ratio of 26.40 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The company’s 50 day simple moving average is $47.87 and its 200 day simple moving average is $33.56.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Ascendiant Capital Markets increased their target price on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 11th. StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th.

Hedge Funds Weigh In On Pro-Dex

Several hedge funds and other institutional investors have recently modified their holdings of PDEX. Ritholtz Wealth Management acquired a new stake in Pro-Dex in the fourth quarter valued at about $572,000. Renaissance Technologies LLC lifted its holdings in shares of Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after acquiring an additional 900 shares during the last quarter. FMR LLC boosted its stake in shares of Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after purchasing an additional 2,296 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after purchasing an additional 3,067 shares during the last quarter. Institutional investors own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.